首页
关于
平台
科学
新闻
投资者关系
联系
中
/
EN
新闻
2026-07-13
天辰生物LP-003花生过敏适应症获美国FDA批准，全球化临床布局取得关键突破
more
2026-07-03
【招贤纳士】生产工艺总监
more
2026-07-03
【招贤纳士】VP of CMC
more
2026-03-25
Superior Efficacy and Long-acting: LongBio Announces Positive Topline Results from Phase II CSU Trial of Next-Generation Anti-IgE Therapy, LP-003 in Head-to-Head Comparison with Omalizumab
more
2024-12-18
Groundbreaking! Phase II Data of LP-003 Unveiled by Longbio Pharma at AAAAI2024
more
1
2
